Determinants of generic drug substitution in Switzerland

<p>Abstract</p> <p>Background</p> <p>Since generic drugs have the same therapeutic effect as the original formulation but at generally lower costs, their use should be more heavily promoted. However, a considerable number of barriers to their wider use have been observe...

Full description

Bibliographic Details
Main Authors: Lufkin Thomas M, Halfon Patricia, Eggli Yves, Decollogny Anne
Format: Article
Language:English
Published: BMC 2011-01-01
Series:BMC Health Services Research
Online Access:http://www.biomedcentral.com/1472-6963/11/17
_version_ 1818756916153679872
author Lufkin Thomas M
Halfon Patricia
Eggli Yves
Decollogny Anne
author_facet Lufkin Thomas M
Halfon Patricia
Eggli Yves
Decollogny Anne
author_sort Lufkin Thomas M
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Since generic drugs have the same therapeutic effect as the original formulation but at generally lower costs, their use should be more heavily promoted. However, a considerable number of barriers to their wider use have been observed in many countries. The present study examines the influence of patients, physicians and certain characteristics of the generics' market on generic substitution in Switzerland.</p> <p>Methods</p> <p>We used reimbursement claims' data submitted to a large health insurer by insured individuals living in one of Switzerland's three linguistic regions during 2003. All dispensed drugs studied here were substitutable. The outcome (use of a generic or not) was modelled by logistic regression, adjusted for patients' characteristics (gender, age, treatment complexity, substitution groups) and with several variables describing reimbursement incentives (deductible, co-payments) and the generics' market (prices, packaging, co-branded original, number of available generics, etc.).</p> <p>Results</p> <p>The overall generics' substitution rate for 173,212 dispensed prescriptions was 31%, though this varied considerably across cantons. Poor health status (older patients, complex treatments) was associated with lower generic use. Higher rates were associated with higher out-of-pocket costs, greater price differences between the original and the generic, and with the number of generics on the market, while reformulation and repackaging were associated with lower rates. The substitution rate was 13% lower among hospital physicians. The adoption of the prescribing practices of the canton with the highest substitution rate would increase substitution in other cantons to as much as 26%.</p> <p>Conclusions</p> <p>Patient health status explained a part of the reluctance to substitute an original formulation by a generic. Economic incentives were efficient, but with a moderate global effect. The huge interregional differences indicated that prescribing behaviours and beliefs are probably the main determinant of generic substitution.</p>
first_indexed 2024-12-18T06:02:38Z
format Article
id doaj.art-6666b305d7cd475aa9a7c6b143f49cd9
institution Directory Open Access Journal
issn 1472-6963
language English
last_indexed 2024-12-18T06:02:38Z
publishDate 2011-01-01
publisher BMC
record_format Article
series BMC Health Services Research
spelling doaj.art-6666b305d7cd475aa9a7c6b143f49cd92022-12-21T21:18:39ZengBMCBMC Health Services Research1472-69632011-01-011111710.1186/1472-6963-11-17Determinants of generic drug substitution in SwitzerlandLufkin Thomas MHalfon PatriciaEggli YvesDecollogny Anne<p>Abstract</p> <p>Background</p> <p>Since generic drugs have the same therapeutic effect as the original formulation but at generally lower costs, their use should be more heavily promoted. However, a considerable number of barriers to their wider use have been observed in many countries. The present study examines the influence of patients, physicians and certain characteristics of the generics' market on generic substitution in Switzerland.</p> <p>Methods</p> <p>We used reimbursement claims' data submitted to a large health insurer by insured individuals living in one of Switzerland's three linguistic regions during 2003. All dispensed drugs studied here were substitutable. The outcome (use of a generic or not) was modelled by logistic regression, adjusted for patients' characteristics (gender, age, treatment complexity, substitution groups) and with several variables describing reimbursement incentives (deductible, co-payments) and the generics' market (prices, packaging, co-branded original, number of available generics, etc.).</p> <p>Results</p> <p>The overall generics' substitution rate for 173,212 dispensed prescriptions was 31%, though this varied considerably across cantons. Poor health status (older patients, complex treatments) was associated with lower generic use. Higher rates were associated with higher out-of-pocket costs, greater price differences between the original and the generic, and with the number of generics on the market, while reformulation and repackaging were associated with lower rates. The substitution rate was 13% lower among hospital physicians. The adoption of the prescribing practices of the canton with the highest substitution rate would increase substitution in other cantons to as much as 26%.</p> <p>Conclusions</p> <p>Patient health status explained a part of the reluctance to substitute an original formulation by a generic. Economic incentives were efficient, but with a moderate global effect. The huge interregional differences indicated that prescribing behaviours and beliefs are probably the main determinant of generic substitution.</p>http://www.biomedcentral.com/1472-6963/11/17
spellingShingle Lufkin Thomas M
Halfon Patricia
Eggli Yves
Decollogny Anne
Determinants of generic drug substitution in Switzerland
BMC Health Services Research
title Determinants of generic drug substitution in Switzerland
title_full Determinants of generic drug substitution in Switzerland
title_fullStr Determinants of generic drug substitution in Switzerland
title_full_unstemmed Determinants of generic drug substitution in Switzerland
title_short Determinants of generic drug substitution in Switzerland
title_sort determinants of generic drug substitution in switzerland
url http://www.biomedcentral.com/1472-6963/11/17
work_keys_str_mv AT lufkinthomasm determinantsofgenericdrugsubstitutioninswitzerland
AT halfonpatricia determinantsofgenericdrugsubstitutioninswitzerland
AT eggliyves determinantsofgenericdrugsubstitutioninswitzerland
AT decollognyanne determinantsofgenericdrugsubstitutioninswitzerland